Prevention of bleeding in hemophilia patients with high-titer inhibitors

Prevention of bleeding in hemophilia patients with high-titer inhibitors

Autor Leissinger, Cindy A. Google Scholar
Konkle, Barbara A. Google Scholar
Antunes, Sandra V. Autor UNIFESP Google Scholar
Instituição Tulane Univ
Blood Works NW
Univ Washington
Universidade Federal de São Paulo (UNIFESP)
Resumo Inhibitor development is the most serious adverse event linked to the treatment of hemophilia, as it renders standard hemostatic therapy ineffective. Consequently, inhibitor patients are at increased risk for difficult-to-control bleeding and complications, particularly arthropathy and physical disability. Three randomized clinical trials in patients with inhibitors have demonstrated that compared with on-demand bypassing therapy, prophylaxis with a bypassing agent reduces joint and other types of bleeding and improves health-related quality of life. in hemophilia patients without inhibitors, the initiation of prophylaxis with factor (F) VIII or IX prior to the onset of recurrent hemarthroses can prevent the development of joint disease. Whether this is also true for bypassing agent prophylaxis remains to be determined.
Assunto activated prothrombin complex concentrate
bypassing agents
factor IX
factor VIII
hemophilia A
hemophilia B
inhibitors
prophylaxis
recombinant activated factor VII
Idioma Inglês
Financiador Baxter
Bayer
CSL Behring
Novo Nordisk
Baxter Healthcare Corp
Data 2015-06-01
Publicado em Expert Review of Hematology. London: Expert Reviews, v. 8, n. 3, p. 375-382, 2015.
ISSN 1747-4086 (Sherpa/Romeo, fator de impacto)
Editor Expert Reviews
Extensão 375-382
Fonte http://dx.doi.org/10.1586/17474086.2015.1036733
Direito de acesso Acesso restrito
Tipo Resenha
Web of Science WOS:000354389000013
URI http://repositorio.unifesp.br/handle/11600/39140

Mostrar registro completo




Arquivos deste item

Arquivos Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item aparece na(s) seguinte(s) coleção(s)